{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:06:17Z","timestamp":1790841977625,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,15]]},"DOI":"10.7759\/cureus.36197","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T16:56:29Z","timestamp":1678899389000},"source":"Crossref","is-referenced-by-count":51,"title":["Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)"],"prefix":"10.7759","author":[{"given":"Tolu","family":"Ogbonmide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid B","family":"Rangrej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stedrea","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephenie","family":"Ojilere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irenaissia","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous O","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, et al.. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther. 2019, 36:1164-76. 10.1007\/s12325-019-00923-8","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/neo.20-8-e437","article-title":"Spinal muscular atrophy: past, present, and future","volume":"20","author":"Ross LF","year":"2019","unstructured":"Ross LF, Kwon JM. Spinal muscular atrophy: past, present, and future. Neoreviews. 2019, 20:e437-51. 10.1542\/neo.20-8-e437","journal-title":"Neoreviews"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow H","year":"2018","unstructured":"Chaytow H, Huang YT, Gillingwater TH, Faller KM. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018, 75:3877-94. 10.1007\/s00018-018-2849-1","journal-title":"Cell Mol Life Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular\u00a0atrophy","volume":"74","author":"Chand D","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, et al.. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular\u00a0atrophy. J Hepatol. 2021, 74:560-6. 10.1016\/j.jhep.2020.11.001","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes LP","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, et al.. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019, 98:39-45. 10.1016\/j.pediatrneurol.2019.05.005","journal-title":"Pediatr Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho M","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al.. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018, 28:208-15. 10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14587","article-title":"Clinical and radiological profile of patients with spinal muscular atrophy type 4","volume":"28","author":"Souza PV","year":"2021","unstructured":"Souza PV, Pinto WB, Ricarte A, et al.. Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol. 2021, 28:609-19. 10.1111\/ene.14587","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold WD","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015, 51:157-67. 10.1002\/mus.24497","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart IE","year":"2017","unstructured":"Verhaart IE, Robertson A, Wilson IJ, et al.. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017, 12:124. 10.1186\/s13023-017-0671-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner J","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, et al.. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020, 28:38-43. 10.1016\/j.ejpn.2020.07.001","journal-title":"Eur J Paediatr Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin CW","year":"2015","unstructured":"Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol. 2015, 53:293-300. 10.1016\/j.pediatrneurol.2015.06.002","journal-title":"Pediatr Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1889841","article-title":"An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)","volume":"9","author":"Dean R","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al.. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021, 9:1889841. 10.1080\/20016689.2021.1889841","journal-title":"J Mark Access Health Policy"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone DC","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al.. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019, 7:1601484. 10.1080\/20016689.2019.1601484","journal-title":"J Mark Access Health Policy"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy S","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, et al.. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019, 54:179-85. 10.1002\/ppul.24203","journal-title":"Pediatr Pulmonol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell JR","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al.. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017, 377:1713-22. 10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"ref16","article-title":"Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update","volume":"2","author":"Strauss K","unstructured":"Strauss K, Muntoni F, Farrar M, et al.. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update. 2, 2:4190-2021."},{"key":"ref17","article-title":"Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA)","volume":"1","author":"Strauss K","unstructured":"Strauss K, Muntoni F, Farrar M, et al.. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA). 1:"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.10.1317","article-title":"Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update","volume":"405","author":"Strauss KA","year":"2019","unstructured":"Strauss KA, Swoboda KJ, Farrar MA, et al.. Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update. J Neurol Sci. 2019, 405:268-9.","journal-title":"J Neurol Sci"},{"key":"ref19","unstructured":"National Institute of Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy. (2021). Accessed: March 13, 2023: https:\/\/smauk.org.uk\/files\/files\/Research\/SMA%20UK%20Zolgensma%20Evaluation%20Consultation%20response%20to%20NICE%20A...."},{"key":"ref20","unstructured":"CureSMA. Zolgensma. Accessed: March 13, 2023: https:\/\/www.curesma.org\/zolgensma\/."},{"key":"ref21","unstructured":"Zolgensma. Symptomatic study results. (2021). Accessed: November 18, 2021: https:\/\/www.zolgensma.com\/clinical-studies\/symptomatic-study-result."},{"key":"ref22","unstructured":"Spinal Muscular Atrophy. Key Zolgensma clinical trials. (2021). Accessed: March 13, 2023: https:\/\/smauk.org.uk\/key-zolgensma-clinical-trials."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy SA","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019, 100:3-11. 10.1016\/j.pediatrneurol.2019.06.007","journal-title":"Pediatr Neurol"},{"key":"ref24","article-title":"The value of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy for spinal muscular atrophy type 1","volume":"15","author":"Dabbous O","year":"2019","unstructured":"Dabbous O, Sproule DM, Feltner DE, et al.. The value of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy for spinal muscular atrophy type 1. Journal of the Neurological Sciences. 2019, 15:59.","journal-title":"Journal of the Neurological Sciences"},{"key":"ref25","unstructured":"Novartis. Zolgensma. (2021). Accessed: November 18, 2021: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/zolgensma.pdf."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00001-6","article-title":"Onasemnogene ABEPARVOVEC gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. The","volume":"20","author":"Day","unstructured":"Day, Finkel, Chiriboga, et al.. Onasemnogene ABEPARVOVEC gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. The. Lancet Neurology. 20:284-293. 10.1016\/s1474-4422(21)00001-6","journal-title":"Lancet Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/140225-gene-therapy-for-spinal-muscular-atrophy-sma-a-review-of-current-challenges-and-safety-considerations-for-onasemnogene-abeparvovec-zolgensma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:55:33Z","timestamp":1707490533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/140225-gene-therapy-for-spinal-muscular-atrophy-sma-a-review-of-current-challenges-and-safety-considerations-for-onasemnogene-abeparvovec-zolgensma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.36197","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}